Inhibitors of PI3Kδ have been approved for treatment of cancer, inflammatory and autoimmune diseases (88), and our data provide rationale to further explore the targeting of the PI3Kδ-TLR8 axis in SSc-PF and IPF, via repurposing drugs used for cancer treatment. This evidence concerns the gene TLR8 and cancer.